Nurix Therapeutics (NRIX) Stock Drops as Roche Announces $2.3 Billion Cancer Drug Partnership

Nurix Therapeutics (NRIX) partners with Roche in $2.3B deal for blood cancer drug bexobrutideg. $700M upfront, Phase III trials begin this summer.

The post Nurix Therapeutics (NRIX) Stock Drops as Roche Announces $2.3 Billion Cancer Drug Partnership appeared first on Blockonomi.